PGNY Earnings Date: Nov 4, 2026 (Estimated) — Progyny, Inc.
NASDAQ · Healthcare · Healthcare Plans
Updated
When is PGNY's next earnings date?
Progyny, Inc. (PGNY) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.31 on revenue of $340.8M.
How did PGNY do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Progyny, Inc. posted EPS of $0.55 versus the $0.33 estimate, a beat of 17.0%. Revenue was $350.5M against a $349.0M estimate. The stock's 1-day post-earnings move was -7.0%.
How much does PGNY stock move after earnings?
PGNY beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 14.5% (up or down) in the day after earnings.
About Progyny, Inc.
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | 0.33 | 0.55 | +17.02% | $350.5M | ✅ Beat | -6.98% | -14.30% | -14.13% |
| 2026-05-07 | Q1 2026 | 0.39 | 0.50 | +28.21% | $328.5M | ✅ Beat | +23.80% | +19.36% | +35.28% |
| 2026-02-26 | Q4 2025 | 0.29 | 0.48 | +65.52% | $318.4M | ✅ Beat | -20.49% | -20.81% | -22.38% |
| 2025-11-06 | Q3 2025 | 0.29 | 0.45 | +55.17% | $313.3M | ✅ Beat | +24.21% | +35.59% | +37.15% |
| 2025-08-07 | Q2 2025 | 0.32 | 0.48 | +50.00% | $332.9M | ✅ Beat | -0.91% | -2.21% | -0.91% |
| 2025-02-27 | Q4 2024 | 0.37 | 0.42 | +13.51% | $298.4M | ✅ Beat | -1.53% | -8.00% | -4.28% |
| 2024-11-12 | Q3 2024 | 0.13 | 0.40 | +207.69% | $286.6M | ✅ Beat | -19.09% | -20.43% | -13.50% |
| 2024-08-06 | Q2 2024 | 0.17 | 0.43 | +152.94% | $304.1M | ✅ Beat | -19.00% | -16.08% | -7.96% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $350.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Fertility benefit services revenue | 65.7% | $230.2M | +7.6% | $381.0M | $206.4M | $213.9M | $201.9M |
| Pharmacy benefit services revenue | 34.3% | $120.3M | +1.2% | $221.5M | $117.6M | $118.9M | $111.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.